cardiometabolic biomarkers

Levothyroxine treatment in older adults with subclinical hypothyroidism shows limited impact on cardiometabolic biomarkers overall but may benefit those with higher TSH levels, highlighting nuanced treatment implications and the need for tailored therapeutic strategies.